Beckman Coulter, Inc. Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	77
ISBN Number	not applicable
Product Code	GMD04788

Price

£490.00
approximately: $749 | €546

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a Beckman Coulter, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
- 2.4 Industry Outlook In Vitro Diagnostics
3 Business Description
- 3.1 Business Overview
- 3.2 Cellular Systems
  - 3.2.1 Overview
  - 3.2.2 Financials
  - 3.2.3 Market View
- 3.3 Chemistry Systems
  - 3.3.1 Overview
  - 3.3.2 Financials
  - 3.3.3 Market View
- 3.4 Immunoassay Systems
  - 3.4.1 Overview
  - 3.4.2 Financials
  - 3.4.3 Market View
  - 3.4.4 Key Strategies
- 3.5 Major Products and Services
  - 3.5.1 Overview
4 History
5 Business Strategy
- 5.1 Mission Statement
- 5.2 Strategy
- 5.3 Corporate Social Responsibility
  - 5.3.1 Overview
  - 5.3.2 Specific CSR Initiatives
6 Value Chain Analysis
- 6.1 Manufacturing
  - 6.1.1 In House Manufacturing
- 6.2 Product Development
  - 6.2.1 Regulatory Approvals
  - 6.2.2 Research and Development
- 6.3 Sales and Marketing
  - 6.3.1 Partnerships and Alliances
  - 6.3.2 Licensing Agreements
7 Competitors
8 Share Holding Structure
9 Key Employees
10 Key Employee Biographies
11 Company Statement
12 Locations And Subsidiaries
- 12.1 Head Office
- 12.2 Other Locations & Subsidiaries
13 Recent Developments
- 13.1 Financial Announcements
  - 13.1.1 Jul 25, 2008: Beckman Reports 2Q 2008 Results
  - 13.1.2 Jul 21, 2008: Beckman Declares Quarterly Dividend
  - 13.1.3 Apr 30, 2008: Beckman Declares Q1 2008 Results
  - 13.1.4 Apr 25, 2008: Beckman Declares Quarterly Dividend
  - 13.1.5 Apr 11, 2008: Beckman To Declare Q1 2008 Results
  - 13.1.6 Feb 08, 2008: Beckman Declares Quarterly Dividend
  - 13.1.7 Feb 08, 2008: Beckman Declares Q4 2007 Results
  - 13.1.8 Jan 23, 2008: Beckman To Declare Q4 2007 Results
  - 13.1.9 Oct 30, 2007: Beckman Declares Q3 2007 Results
  - 13.1.10 Oct 22, 2007: Beckman Declares Quarterly Dividend
  - 13.1.11 Aug 01, 2007: Beckman Declares Q2 2007 Results
  - 13.1.12 Jul 26, 2007: Beckman Declares Quarterly Dividend
  - 13.1.13 May 03, 2007: Beckman Declares Quarterly Dividend
  - 13.1.14 May 02, 2007: Beckman Q1 Revenue Up 7.8% To $613.6 Million
  - 13.1.15 Mar 26, 2007: Beckman Coulter Declares Q4 Results
  - 13.1.16 Jan 10, 2007: Beckman Coulter Streamlines Operations
  - 13.1.17 Nov 01, 2006: Beckman Coulter Announces Q3 2006 Results
  - 13.1.18 Aug 02, 2006: Beckman Coulter Announces Q2 2006 Results
- 13.2 Corporate Communications
  - 13.2.1 Feb 08, 2008: Beckman Names New Chairman
  - 13.2.2 Dec 12, 2007: Beckman Elects New Board Member
  - 13.2.3 Jun 04, 2007: Beckman Board Member Resigns
  - 13.2.4 Oct 10, 2006: Beckman Coulter Appoints New Vice President and CFO
- 13.3 Legal and Regulatory
  - 13.3.1 Aug 01, 2006: Beckman Announces Arbitration Results With Digene
  - 13.3.2 Apr 27, 2006: Beckman Coulter Provides Information On Applera Settlement
- 13.4 Product News
  - 13.4.1 Mar 07, 2008: Beckman Coulter, Inc. Releases The High-Volume UniCel DxC 880i Integrated Work Cell
  - 13.4.2 Jan 21, 2008: Minister Martin Announces Significant R&D Collaboration For Beckman Coulter And NUI Galway
  - 13.4.3 Jan 21, 2008: Minister Martin Announces Significant R&D Collaboration For Beckman Coulter And NUI Galway
  - 13.4.4 Jan 21, 2008: Minister Martin Announces Significant R&D Collaboration For Beckman Coulter And NUI Galway
  - 13.4.5 Jan 31, 2007: Beckman Coulter Integrates New BioRAPTR Workstation for High-Throughput Assay Miniaturization
  - 13.4.6 Nov 20, 2006: Beckman Coulter's EPO Assay Approved By FDA
  - 13.4.7 Jan 01, 2005: Beckman Coulter Offers Cyanide-Free Reagents for COULTER LH 500 Hematology Analyzer
  - 13.4.8 Jan 01, 2005: Beckman Coulters New Version of DL2000 Data Manager Boasts Enhanced Features for Improved Laboratory Workflow
  - 13.4.9 Oct 01, 2004: 21 CFR Part 11 Software for Automated Benchtop Flow Cytometry System
  - 13.4.10 May 04, 2004: Beckman Coulter Launches High-Volume ACL TOP Coagulation Analyzer With Extensive Test Menu
  - 13.4.11 Aug 08, 2003: Beckman Coulter Announces New GenomeLab Initiative
  - 13.4.12 Aug 01, 1999: Newest COULTER HmX Hematology Flow Cytometer
- 13.5 Product Approvals
  - 13.5.1 Nov 20, 2006: Beckman Coulter's EPO Assay Approved By FDA
- 13.6 Other Significant Developments
  - 13.6.1 Nov 07, 2007: Beckman Signs Agreements With MedAssets
  - 13.6.2 Apr 02, 2007: Beckman Signs Pact With Premier To Provide Core Laboratory Systems
14 Beckman Coulter, Inc. Pipeline Products
- 14.1 Beckman Coulter, Inc. Product Pipeline Analysis
  - 14.1.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
  - 14.1.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
  - 14.1.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
  - 14.1.4 Beckman Coulter, Inc. Pipeline Products By News Summary
- 14.2 Sex Hormone Binding Globulin Test
  - 14.2.1 Product Description
  - 14.2.2 Product Status
- 14.3 sVEGF-R1
  - 14.3.1 Product Description
  - 14.3.2 Product Status
- 14.4 EPO assay
  - 14.4.1 Product Description
  - 14.4.2 Product Status
  - 14.4.3 Product Milestone
- 14.5 ProClot (Protein C) for ACL TOP
  - 14.5.1 Product Description
  - 14.5.2 Product Status
- 14.6 ProS (Protein S) for ACL TOP
  - 14.6.1 Product Description
  - 14.6.2 Product Status
- 14.7 Tricyclics
  - 14.7.1 Product Description
  - 14.7.2 Product Status
- 14.8 Ischemia Modified Albumin
  - 14.8.1 Product Description
  - 14.8.2 Product Status
- 14.9 ANA Screen
  - 14.9.1 Product Description
  - 14.9.2 Product Status
- 14.10 Soluble Transferrin Receptor
  - 14.10.1 Product Description
  - 14.10.2 Product Status
- 14.11 PT-Fib for ACL TOP
  - 14.11.1 Product Description
  - 14.11.2 Product Status
- 14.12 PT-Fib HS for ACL TOP
  - 14.12.1 Product Description
  - 14.12.2 Product Status
- 14.13 PT-Fib HS Plus for ACL TOP
  - 14.13.1 Product Description
  - 14.13.2 Product Status
- 14.14 Rubella IgM
  - 14.14.1 Product Description
  - 14.14.2 Product Status
- 14.15 Anti-Cardiolipin
  - 14.15.1 Product Description
  - 14.15.2 Product Status
- 14.16 ds DNA Ab
  - 14.16.1 Product Description
  - 14.16.2 Product Status
- 14.17 Inhibin A
  - 14.17.1 Product Description
  - 14.17.2 Product Status
- 14.18 Anti-dsDNA
  - 14.18.1 Product Description
  - 14.18.2 Product Status
- 14.19 Immunoassay for sepsis
  - 14.19.1 Product Description
  - 14.19.2 Product Status
- 14.20 Tests for hospital acquired infections
  - 14.20.1 Product Description
  - 14.20.2 Product Institution Details
  - 14.20.3 Product Status
  - 14.20.4 Product Milestone
- 14.21 Chlamydia test
  - 14.21.1 Product Description
  - 14.21.2 Product Institution Details
  - 14.21.3 Product Status
  - 14.21.4 Product Milestone
- 14.22 Neisseria test
  - 14.22.1 Product Description
  - 14.22.2 Product Institution Details
  - 14.22.3 Product Status
  - 14.22.4 Product Milestone
15 Appendix
- 15.1 Methodology
  - 15.1.1 Coverage
  - 15.1.2 Secondary Research
  - 15.1.3 Primary Research
  - 15.1.4 Expert Panel Validation
- 15.2 Contact Us
- 15.3 About Global Markets Direct
- 15.4 Disclaimer
1 List of Tables
- Table 1: Beckman Coulter, Inc.,Key Facts, 2007
- Table 2: Beckman Coulter, Inc., Share Holding Structure
- Table 3: Beckman Coulter, Inc., Key Employees, 2007
- Table 4: Beckman Coulter, Inc., Other Locations
- Table 5: Beckman Coulter, Inc., Subsidiaries
- Table 6: Beckman Coulter, Inc. Pipeline Products by Equipment Type
- Table 7: Beckman Coulter, Inc. Pipeline Products By Development Stage
- Table 8: Beckman Coulter, Inc. Pipeline Products By Therapy Area
- Table 9: Beckman Coulter, Inc. Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: Beckman Coulter, Inc., Value Chain Analysis
- Figure 2: Beckman Coulter, Inc. Pipeline Products By Equipment Type
- Figure 3: Beckman Coulter, Inc. Pipeline Products By Equipment Type
- Figure 4: Beckman Coulter, Inc. Pipeline Products By Development Stage
- Figure 5: Global Markets Direct Methodology